742 related articles for article (PubMed ID: 17470580)
1. First-trimester ultrasonographic screening for trisomy 21 using fetal nuchal translucency and nasal bone.
Sepulveda W; Wong AE; Dezerega V
Obstet Gynecol; 2007 May; 109(5):1040-5. PubMed ID: 17470580
[TBL] [Abstract][Full Text] [Related]
2. Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening.
Nicolaides KH; Spencer K; Avgidou K; Faiola S; Falcon O
Ultrasound Obstet Gynecol; 2005 Mar; 25(3):221-6. PubMed ID: 15736186
[TBL] [Abstract][Full Text] [Related]
3. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH
Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
[TBL] [Abstract][Full Text] [Related]
4. Nuchal translucency and nasal bone for trisomy 21 screening: single center experience.
Monni G; Zoppi MA; Ibba RM; Floris M; Manca F; Axiana C
Croat Med J; 2005 Oct; 46(5):786-91. PubMed ID: 16158472
[TBL] [Abstract][Full Text] [Related]
5. If nuchal translucency screening is combined with first-trimester serum screening the need for fetal karyotyping decreases.
Marsk A; Grunewald C; Saltvedt S; Valentin L; Almström H
Acta Obstet Gynecol Scand; 2006; 85(5):534-8. PubMed ID: 16752230
[TBL] [Abstract][Full Text] [Related]
6. Sonographic screening for trisomy 13 at 11 to 13(+6) weeks of gestation.
Papageorghiou AT; Avgidou K; Spencer K; Nix B; Nicolaides KH
Am J Obstet Gynecol; 2006 Feb; 194(2):397-401. PubMed ID: 16458636
[TBL] [Abstract][Full Text] [Related]
7. [Study on several ultrasound markers combined maternal serum biochemical markers to screen fetal chromosomal aneuploidy at 11 to 13(+)6 weeks of gestation].
Chen X; Chang Y; Cui HY; Ren CC; Yu BY
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):815-8. PubMed ID: 24444556
[TBL] [Abstract][Full Text] [Related]
8. Fetal nasal bone in screening for trisomies 21, 18 and 13 and Turner syndrome at 11-13 weeks of gestation.
Kagan KO; Cicero S; Staboulidou I; Wright D; Nicolaides KH
Ultrasound Obstet Gynecol; 2009 Mar; 33(3):259-64. PubMed ID: 19248005
[TBL] [Abstract][Full Text] [Related]
9. The utility of detailed first trimester ultrasound examination in abnormal fetal nuchal translucency.
Bronshtein M; Zimmer EZ; Blazer S
Prenat Diagn; 2008 Nov; 28(11):1037-41. PubMed ID: 18925580
[TBL] [Abstract][Full Text] [Related]
10. Second-trimester prenatal screening for trisomy 21 using biochemical markers: a 7-year experience in one cytogenetic laboratory.
Marical H; Douet-Guilbert N; Bages K; Collet M; Le Bris MJ; Morel F; De Braekeleer M
Prenat Diagn; 2006 Apr; 26(4):308-12. PubMed ID: 16491510
[TBL] [Abstract][Full Text] [Related]
11. First-trimester ductus venosus, nasal bones, and Down syndrome in a high-risk population.
Prefumo F; Sethna F; Sairam S; Bhide A; Thilaganathan B
Obstet Gynecol; 2005 Jun; 105(6):1348-54. PubMed ID: 15932828
[TBL] [Abstract][Full Text] [Related]
12. Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Kagan KO; Wright D; Maiz N; Pandeva I; Nicolaides KH
Ultrasound Obstet Gynecol; 2008 Sep; 32(4):488-92. PubMed ID: 18726925
[TBL] [Abstract][Full Text] [Related]
13. First- and second-trimester screening: detection of aneuploidies other than Down syndrome.
Breathnach FM; Malone FD; Lambert-Messerlian G; Cuckle HS; Porter TF; Nyberg DA; Comstock CH; Saade GR; Berkowitz RL; Klugman S; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; Tripp T; Bianchi DW; D'Alton ME;
Obstet Gynecol; 2007 Sep; 110(3):651-7. PubMed ID: 17766613
[TBL] [Abstract][Full Text] [Related]
14. Association of fetal choroid plexus cysts with trisomy 18 in a population previously screened by nuchal translucency thickness measurement.
Cheng PJ; Shaw SW; Soong YK
J Soc Gynecol Investig; 2006 May; 13(4):280-4. PubMed ID: 16697944
[TBL] [Abstract][Full Text] [Related]
15. Evidence-based obstetric ethics and informed decision-making by pregnant women about invasive diagnosis after first-trimester assessment of risk for trisomy 21.
Nicolaides KH; Chervenak FA; McCullough LB; Avgidou K; Papageorghiou A
Am J Obstet Gynecol; 2005 Aug; 193(2):322-6. PubMed ID: 16098850
[TBL] [Abstract][Full Text] [Related]
16. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics.
Kagan KO; Wright D; Spencer K; Molina FS; Nicolaides KH
Ultrasound Obstet Gynecol; 2008 May; 31(5):493-502. PubMed ID: 18432600
[TBL] [Abstract][Full Text] [Related]
17. Relation between increased fetal nuchal translucency thickness and chromosomal defects.
Kagan KO; Avgidou K; Molina FS; Gajewska K; Nicolaides KH
Obstet Gynecol; 2006 Jan; 107(1):6-10. PubMed ID: 16394033
[TBL] [Abstract][Full Text] [Related]
18. [The prenatal detection of trisomy 13, 18, and 21: comparison of the advanced first trimester screening (AFS) with the first trimester screening according to Nicolaides].
Hörmansdörfer C; Schmidt P; Hillemanns P; Scharf A
Z Geburtshilfe Neonatol; 2007 Dec; 211(6):243-9. PubMed ID: 18176905
[TBL] [Abstract][Full Text] [Related]
19. Nuchal translucency and nasal bone in first-trimester ultrasound screening for aneuploidy in multiple pregnancies.
Sepulveda W; Wong AE; Casasbuenas A
Ultrasound Obstet Gynecol; 2009 Feb; 33(2):152-6. PubMed ID: 18985621
[TBL] [Abstract][Full Text] [Related]
20. Nuchal fold thickness, nasal bone absence or hypoplasia, ductus venosus reversed flow and tricuspid valve regurgitation in screening for trisomies 21, 18 and 13 in the early second trimester.
Geipel A; Willruth A; Vieten J; Gembruch U; Berg C
Ultrasound Obstet Gynecol; 2010 May; 35(5):535-9. PubMed ID: 20183867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
